Safely2Prosperity Expands Partnership with Digital Diagnostic Test Provider Ellume

NEWS RELEASE

CONTACT:

John Norris

617-680-3127

John.Norris@Safely2Prosperity.com

https://www.safely2prosperity.com



Top COVID-19 Risk Manager Safely2Prosperity Partners More Broadly with Australia and US-Based Digital Diagnostic Test Provider Ellume

July 21, 2022 – Boston, MA USA


TODAY, Safely2Prosperity LLC (S2P) Founder and Executive Chairman John Norris, JD, MBA, and CEO John Covender are pleased to announce the addition to S2P's product offerings of the Ellume COVID-19 Home Test (ECHT), a premium, reliable, affordable, and easy-to-use COVID-19 diagnostic testing product developed by Ellume.


Earlier this year, Ellume opened its U.S.-based manufacturing facility in Frederick, Maryland, building upon an existing state-of-the-art facility in Brisbane, Australia. S2P is gold-ranked globally as a digital COVID-19 enterprise risk management innovator, developer, and hands-on manager. Ellume develops, manufactures, and commercializes the next generation of digitally enabled diagnostic products for healthcare professionals and consumers.


The ECHT product detects the commonly occurring known COVID-19 variants to date and is suitable for ages two years and above. It is a premium, high-impact, highly automated, easy-to-use "add-on solution" to help S2P prepare, install, prevent, oversee, detect, mitigate, control, and record enterprise infectious disease spread within enterprises and within countries starting with COVID-19 and its variants and sub-variants.


Because of its unique and easy-to-use features, Ellume's test, along with S2P's earlier addition to its platform, VXPASS, also helps S2P prevent, mitigate, and control fraud or error in authenticating the test, vaccination, and therapy status of those employees (or their family members) seeking entry into a work facility, floor, or shift. With the addition of the Ellume test to S2P's Enterprise Infectious Disease Software-as-a-Service (SaaS) Safety Platform, US and global enterprises can better ensure a safer, highly automated, more administrable, more productive, more recordable, and more financially secure workplace, thereby saving enterprises, investors, and jobs, and those who make themselves available to fill them (and their families) from harm.


Using this world-class Ellume product in conjunction with S2P's Safety Program will help protect employers in many ways. For example, the employer will be able to better defend its company's and investor's finances, brand, and attractiveness to current and recruited employees, while helping to protect the livelihoods of its employees and families.


As a result, the employer will fulfill its strategic, financial, social, and legal duties and lower its immediate and long-term (1) health insurance, business interruption insurance (or purchased or self-insured alternative), and liability insurance costs, (2) rate of lost productivity, (3) risk of bankruptcy or closure, and (4) levels of liability for negligence, recklessness, or intentional tort cases filed by its employees, families, visitors, investors, and regulators.


The addition of the ECHT product to S2P's risk management system is significant. This sophisticated testing product will boost S2P's further development and market share of its COVID-19 Infectious Disease Risk Management Safety Program Platform and Employee Dashboard. S2P's Software-as-a-Service (SaaS) system is the world's first comprehensive, 24/7 COVID-19 (and variants) enterprise risk management safety program that is nearly fully managed by an outside service. It is a service capable of reliably relieving CEOs, COOs, CFOs, CIOs, and CHROs from most of the complexity and associated stress of the almost impossible job of managing these complex risks on their own.


Without S2P's skilled preparation of their enterprise or country and S2P's use of an advanced, sophisticated, and reasonably priced set of tools on their behalf, these executives will be doomed from the very start. When the next wave hits this Fall, most intelligent enterprises and countries will be prepared and have the crisis managed by S2P for them.


To perform these functions, S2P's Safety Program uses its SaaS infectious disease risk-management platform and add-ons to its platform, such as the Ellume COVID-19 Home Test, and the VXPASS authentication tool, to provide employers with infectious disease-related:

1. End-to-end structured preparation, oversight, and management.

2. Improved, highly automated, easy-to-use monitoring and tracking, including multi-dashboard custom reports.

3. Effective preparations, preventions, mitigations, controls, and other tools, including facility, floor, and shift-based alarms, alerts, trends, and other reports—all based on continuous, 24/7 risk monitoring and risk assessments.

4. Documented and protected legal proof of efforts to protect and comply, critical components of legal defense in audit and liability cases.


S2P's advanced platform empowers the whole organization – from CEOs to CHROs to employees themselves – to manage their COVID-19 responses as mostly delegated to S2P's skilled team. In addition, S2P helps enterprises to assess and report on the risks, actions, and inactions at all levels of the organization: from department to facility to leader to floor to shift to team.


In combination with S2P, the Ellume COVID-19 Home Test will help assure management that their employees—even though their vaccinations, tests, and treatments are, of necessity, administered on a highly complex, staggered basis—are up to date on compliance with their COVID-19 testing, vaccination, and therapy administration schedules. And therefore, they and their coworkers are safer. In addition, it fits well with S2P's advanced technology and is critical to fulfilling S2P's broader safety mission to enterprises, workers, families, investors, and economies.


The overarching goal: Getting back to work. Safely! And at the same time sustaining productivity, profits, and jobs.


Ellume's US Senior Vice President of Business Development, Dan Mallon, said:


"We are pleased to partner with S2P to further the important mission of ensuring the safety and security of workplaces everywhere. The Ellume COVID-19 Home Test has unique data reporting capabilities that allow results to be anonymized, encrypted, and then shared by mutual consent. These capabilities enable employees and enterprises to easily update and prove the integrity of their results on a moment's notice."


S2P Founder and Executive Chairman, and former US Food and Drug Administration's (FDA's) Principal Deputy Commissioner and Chief Operating Officer and Harvard faculty member, John Norris said:


"In every way—from vision to idea to invention to production to sale to distribution to operation to recording—Ellume has created a highly impactful product offering. This world-class product, combined with S2P's Enterprise Infectious Disease Safety Program, will help protect employers, employees, families, investors, and economies. And especially for enterprises, it will lower health insurance costs, lost productivity rates, and liability levels for negligence, recklessness, or intentional tort. In addition, S2P's extensive use of the Ellume COVID-19 Home Test product will aid our rapidly growing infectious disease risk-management company in accomplishing swift growth. But, most of all, featuring a top-of-line testing product like the Ellume COVID-19 Home Test will assist Safely2Prosperity's Gold Standard, SaaS-Driven, Enterprise Infectious-Disease Risk-Management Safety Program to reach its full potential, not just financially, but in terms of its overriding goal of saving employers', employees', families', and economies' lives, in every sense of that word."


S2P CEO Covender said:


"I am pleased to have the Ellume COVID-19 Home Test join S2P's premium slate of product offerings. Together, they empower the whole manufacturer, warehouser, distributor, university/school system, or government-agency enterprise—or a country's government—to better manage their COVID-19 responsibilities. And make their responses more efficiently, safely, and effectively. As well as with far less stress because S2P will itself assume the management of most of the needed efforts. These structures and actions will produce better enterprise and government financial and social ends. But, equally important, we will renew workers' faith in their employers and their countries. And give them renewed confidence in the safety of their families, something extensive research has shown to be the greatest thing on their minds and causing them the most fear."


To arrange an informed discussion, demonstration, and "sandbox trial" of the combined S2P Platform and the Ellume COVID-19 Home Test, contact S2P at 617-680-3127 or info@safely2prosperity.com. Or visit our website at safely2prosperity.com or John Norris at 617-680-3127 or john.norris@safely2prosperity.com.

Getting employees back to work. Safely!


Investing smartly in the safety of employees. We save lives. And we protect employers and investors, their profitability, and their jobs.


With even one life saved or just one lawsuit prevented or mitigated, S2P's solution more than pays for itself.

According to the World-Renowned Healthcare Leader, Fred Hassan: "John Norris and S2P Have a Powerful Vision."

"The best buy-in occurs with bottom-up COVID-19 initiatives. So, we now need comprehensive, bottom-up initiatives and supporting tools for companies, schools, government agencies, and governments to fight better against the current pandemic and the next and the next."

Fred Hassan, Former Chairman of PhRMA and President of IFPMA,

two of the world's leading pharmaceutical,

biotechnology, and related industry advocacy groups.



ABOUT Safely2Prosperity

S2P is a leading digital innovator and solutions provider based in the US (Boston). It provides innovative digital solutions for healthcare risk management through cloud-based software as a business, government agency, and government risk-management system for next-generation infectious disease management. S2P's hands-on management of enterprise and country contagious disease preparedness, oversight, prevention, detection, mitigation, control, and recording tools are included here. S2P's Executive Chairman, John Norris, JD, MBA, is a world-renowned thought leader in health and medical risk management. He is a former Principal Deputy Commissioner and COO of the US FDA and Harvard faculty member. In addition, Mr. Norris has served in many other highly responsible and prominent positions as a CEO, COO, board chairman or member, or outside chief advisor. S2P can be reached at https://www.safely2prosperity.com/. John Norris, JD, MBA, can be reached at: 617-680-3127 or john.norris@safely2prosperity.com


ABOUT ELLUME Ellume is a digital diagnostics company that develops, manufactures, and commercializes modestly-priced, high-performance, connected products for public and private employers, healthcare professionals, and consumers. It is at the forefront of accurate, rapid, and accessible testing that is integral to today's COVID-19 response and will help ensure the world, including its people, employers, governments, and economies, is prepared for the next wave of COVID-19 or other infectious disease pandemics. Ellume's key focus is detecting common contagious diseases affecting the global population. Ellume has a partnership with global diagnostic company QIAGEN for the detection of COVID-19 and Tuberculosis (TB), as well as a range of professional-use products under its ellume·lab brand. Ellume is committed to developing high-quality digital diagnostics that the world can rely on in a health crisis.


In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under a EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C.360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

© 2022 Safely2Prosperity LLC and John Norris, JD, MBA. All Rights Reserved.

6 views0 comments

Discover S2P's solution for workplace COVID safety

More S2P

Never miss an update

Thanks for submitting!